Cholinergic Neurotransmission in the Brain of Streptozotocin-induced Rat Model of Sporadic Alzheimer's Disease: Long-term Follow Up

Overview

Journal J Neural Transm (Vienna)

Date 2025 Feb 1

PMID 39891708

Authors

Ana Knezovic

Melita Salkovic-Petrisic

Affiliations

Soon will be listed here.

Abstract

Rats treated intracerebroventricularly with streptozotocin (STZ-icv) develop pathologic features, which resemble those in Alzheimer's disease and have been proposed as a non-transgenic model for sporadic type of the disease (sAD). We aimed to characterize cholinergic transmission in the rat brain as a function of STZ-icv dose and time after the treatment. Acetylcholinesterase (AChE) activity and expression of muscarinic (M1, M4) and nicotinic (α7) receptors, cholin acetyltransferase (ChAT) and glial fibrillary acidic protein (GFAP) were measured in hippocampus (HPC) and parietotemporal cortex (CTX) of STZ-icv and age-matched control rats one week, and one, three, six and nine months after the icv administration of STZ (0.3, 1 and 3 mg/kg), respectively. Cholinergic and astroglial changes were found most pronounced with a highest STZ dose in time-dependent manner. The cortex and hippocampus exhibited specific alterations in cholinergic transmission following STZ-icv administration, with either similar or distinct patterns depending on the parameter observed: increased AChE activity in HPC and invariable in CTX; increased M4 and ChAT levels in both regions; substantial cortical M1 level increment and moderate hippocampal M1 decrement; and decreased α7 levels in both regions, with subsequent increase observed only in HPC. Alterations in cerebral cholinergic neurotransmission in STZ-icv rat model were mostly following a threephasic time pattern: acute response (Phase I), complete/partial compensation (Phase II), and reappearance/progression of changes (Phase III). Staging structure of cholinergic changes in STZ-icv rat model might be speculated to partly correlate with cholinergic pathology in clinical AD stages.

References

Agrawal R, Tyagi E, Shukla R, Nath C . Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol. 2011; 21(3):261-73. DOI: 10.1016/j.euroneuro.2010.11.009. View

Agrawal M, Perumal Y, Bansal S, Arora S, Chopra K . Phycocyanin alleviates ICV-STZ induced cognitive and molecular deficits via PI3-Kinase dependent pathway. Food Chem Toxicol. 2020; 145:111684. DOI: 10.1016/j.fct.2020.111684. View

Akhtar A, Dhaliwal J, Sah S . 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer's disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology (Berl). 2021; 238(7):1991-2009. DOI: 10.1007/s00213-021-05826-7. View

Scott Andrews J, Desai U, Kirson N, Zichlin M, Ball D, Matthews B . Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2019; 5:354-363. PMC: 6690415. DOI: 10.1016/j.trci.2019.06.005. View

Aslan M, Ozben T . Reactive oxygen and nitrogen species in Alzheimer's disease. Curr Alzheimer Res. 2005; 1(2):111-9. DOI: 10.2174/1567205043332162. View

Babic Perhoc A, Osmanovic Barilar J, Knezovic A, Farkas V, Bagaric R, Svarc A . Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. Neuropharmacology. 2018; 148:50-67. DOI: 10.1016/j.neuropharm.2018.12.018. View

Baskin D, Browning J, Pirozzolo F, Korporaal S, Baskin J, Appel S . Brain choline acetyltransferase and mental function in Alzheimer disease. Arch Neurol. 1999; 56(9):1121-3. DOI: 10.1001/archneur.56.9.1121. View

Bierer L, Haroutunian V, Gabriel S, Knott P, Carlin L, Purohit D . Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995; 64(2):749-60. DOI: 10.1046/j.1471-4159.1995.64020749.x. View

Boller F, Forette F . Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. Biomed Pharmacother. 1989; 43(7):487-91. DOI: 10.1016/0753-3322(89)90109-1. View

10.

Brown A, Bradley S, Marshall F, Brown G, Bennett K, Brown J . From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. Cell. 2021; 184(24):5886-5901.e22. PMC: 7616177. DOI: 10.1016/j.cell.2021.11.001. View

11.

Carvajal F, Inestrosa N . Interactions of AChE with Aβ Aggregates in Alzheimer's Brain: Therapeutic Relevance of IDN 5706. Front Mol Neurosci. 2011; 4:19. PMC: 3172730. DOI: 10.3389/fnmol.2011.00019. View

12.

Chen Z, Huang J, Yang S, Hong F . Role of Cholinergic Signaling in Alzheimer's Disease. Molecules. 2022; 27(6). PMC: 8949236. DOI: 10.3390/molecules27061816. View

13.

Costa M, Bernardi J, Fiuza T, Costa L, Brandao R, Pereira M . N-acetylcysteine protects memory decline induced by streptozotocin in mice. Chem Biol Interact. 2016; 253:10-7. DOI: 10.1016/j.cbi.2016.04.026. View

14.

Counts S, He B, Che S, Ikonomovic M, DeKosky S, Ginsberg S . Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol. 2007; 64(12):1771-6. DOI: 10.1001/archneur.64.12.1771. View

15.

Davis K, Mohs R, Marin D, Purohit D, Perl D, Lantz M . Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999; 281(15):1401-6. DOI: 10.1001/jama.281.15.1401. View

16.

De Felice F, Ferreira S . Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014; 63(7):2262-72. DOI: 10.2337/db13-1954. View

17.

de la Monte S, Wands J . Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2009; 2(6):1101-13. PMC: 2769828. DOI: 10.1177/193229680800200619. View

18.

DeKosky S, Ikonomovic M, Styren S, Beckett L, Wisniewski S, Bennett D . Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002; 51(2):145-55. DOI: 10.1002/ana.10069. View

19.

Dennis S, Pasqui F, Colvin E, Sanger H, Mogg A, Felder C . Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. Cereb Cortex. 2015; 26(1):414-26. PMC: 4677984. DOI: 10.1093/cercor/bhv227. View

20.

Dineley K, Westerman M, Bui D, Bell K, Ashe K, Sweatt J . Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001; 21(12):4125-33. PMC: 6762764. View